Neurotrope BioScience CSO Dr. Daniel Alkon to be Interviewed Live Today on 'Varney & Co.' on Fox Business Read More...
NEW YORK, April 13, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer, will be interviewed live this morning by Stuart Varney on the Fox Business Network program, 'Varney & Co.'
Details of the broadcast are as follows:
Date: Thursday April 13th, 2017
Start Time: 11:45 am EDT
Network: Fox Business Network
Show: Varney & Co.
Host: Stuart Varney
Dr. Alkon will discuss the 'Neurotrope Difference.' Other companies targeting Alzheimer's and other neurodegenerative diseases target one mechanism of action. Neurotrope, through the upregulation of PKC epsilon, activates a multimodal mechanism of action targeting many pathways to stop the spread of toxic plaque and tau tangles while also regenerating synapses by activating Neurotrophic growth factors like BDNF, IGF-1, and NGF.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.
Neurotrope is conducting a Phase 2 trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Sydrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
Forward-Looking Statements
